Figure 3 showed that ACBD3 expression was statistically different among the immune subtypes of nine tumors, including BLCA (Fig. 3A), HNSC (Fig. 3B), STAD (Fig. 3C), SKCM (Fig. 3D), sarcoma (SARC) (Fig. 3E), ovarian serous cystadenocarcinoma (OV) (Fig. 3F), LUSC (Fig. 3G), LIHC (Fig. 3H), and GBM (Fig. 3I). This evidence concerns the gene ACBD3 and glioblastoma.